Rhinomed is a global medical device company enhancing respiration, sleep, diagnosis of upper respiratory disease and nasal drug delivery.

Rhinomed Limited engages in the research, development, and commercialization of consumer and medical devices worldwide. It offers wearable nasal technology that improve breathing, sleeping, and maintaining health and diagnose disease. The company's products include Turbine for enhanced breathing in sports; Mute, which helps to breath more and snore less; Pronto, a vapor inhaler to improve airflow and better sleep; and Rhinoswab that is used to collect a nasal swab. It also engages in developing programs in various markets, including sleep and sleep architecture, the impact of sleep and respiratory, function on cognitive issues, obstructive sleep apnea, pain, nausea, respiratory disease, and diagnostics and sensors; and offers a drug delivery platform for the delivery of cannabinoid formulations. The company was formerly known as Consegna Group Limited and changed its name to Rhinomed Limited in November 2013. Rhinomed Limited was incorporated in 2004 and is headquartered in Cremorne, Australia.

GLOBAL:RHINOMED

Rhinomed

Last Close

0.04

14/02 04:41

Market Cap

11.47M

Beta: -

Volume Today

217.26K

Avg: -

locale

market

industry

website

ipo date

peer of

competitor of

Metrics